Brief: Celyad Oncology: Preliminary Data From IMMUNICY-1 trial of CYAD-211

Celyad Oncology SA

11/06/2021 08:46

June 11 (Reuters) - Celyad Oncology SA  CYAD.BR :
    * CELYAD ONCOLOGY PRESENTS PRELIMINARY DATA FROM PHASE 1
IMMUNICY-1 TRIAL OF SHRNA-BASED ALLOGENEIC CAR T CANDIDATE
CYAD-211 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT THE EUROPEAN
HEMATOLOGY ASSOCIATION VIRTUAL CONGRESS
    * TREATMENT WITH CYAD-211 GENERALLY WELL-TOLERATED AT FIRST
TWO
DOSE LEVELS
    * CELL ENGRAFTMENT OF CYAD-211 OBSERVED IN ALL PATIENTS FROM
DOSE
LEVEL 2, WITH EVIDENCE OF CAR T CELLS IN ALL PATIENTS ENROLLED
IN FIRST TWO DOSE COHORTS
    * TWO PARTIAL RESPONSES OBSERVED AMONG FIVE EVALUABLE
PATIENTS
    * ADDITIONAL CLINICAL DATA FROM DOSE ESCALATION TRIAL ARE
EXPECTED
DURING SECOND HALF 2021

Source text for Eikon:  ID:nGNX32SHRF 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))